[
  {
    "bcr_patient_uuid": "8C54FCFD-999F-43C5-B31F-26D006F5FFF3",
    "patient_ID": "TCGA.D3.A1Q1",
    "bcr_drug_barcode": "TCGA-D3-A1Q1-D32608",
    "bcr_drug_uuid": "A837F724-5440-4324-A350-41DB9FB876E7",
    "form_completion_date": "2012-10-2",
    "pharmaceutical_therapy_drug_name": "CYCLOPHOSPHAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 247,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 341,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "8C54FCFD-999F-43C5-B31F-26D006F5FFF3",
    "patient_ID": "TCGA.D3.A1Q1",
    "bcr_drug_barcode": "TCGA-D3-A1Q1-D40541",
    "bcr_drug_uuid": "18E0B29D-583C-4DD8-A867-71C28698BD3F",
    "form_completion_date": "2013-2-22",
    "clinical_trial_drug_classification": "MELANOMA-DERIVED HELPER PEPTIDES",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 247,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 341,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "8C54FCFD-999F-43C5-B31F-26D006F5FFF3",
    "patient_ID": "TCGA.D3.A1Q1",
    "bcr_drug_barcode": "TCGA-D3-A1Q1-D40542",
    "bcr_drug_uuid": "DFD48E5E-C360-498A-B863-642E648C85A2",
    "form_completion_date": "2013-2-22",
    "clinical_trial_drug_classification": "CLASS I MHC RESTRICTED PEPTIDE BASED VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 247,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 341,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "29476D6A-0D06-4A18-8910-C0502F6539FF",
    "patient_ID": "TCGA.D3.A1Q3",
    "bcr_drug_barcode": "TCGA-D3-A1Q3-D38975",
    "bcr_drug_uuid": "762FC34B-A295-4E09-97E7-2C3D3B8C26BC",
    "form_completion_date": "2013-1-7",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 362,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 362,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1E05DA2E-7DD7-4C98-9E77-59514E5F2582",
    "patient_ID": "TCGA.D3.A1Q6",
    "bcr_drug_barcode": "TCGA-D3-A1Q6-D32615",
    "bcr_drug_uuid": "8036ED31-A3E0-4F53-A74D-144AA41A7CE6",
    "form_completion_date": "2012-10-2",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 111,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 476,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "798074D3-0B84-4DD5-AA88-91FEDA9AC8C6",
    "patient_ID": "TCGA.D3.A1Q9",
    "bcr_drug_barcode": "TCGA-D3-A1Q9-D35421",
    "bcr_drug_uuid": "15D5B49C-2D37-4943-B44E-90D166DFE2EF",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "LUPRON",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 356,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 504,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "798074D3-0B84-4DD5-AA88-91FEDA9AC8C6",
    "patient_ID": "TCGA.D3.A1Q9",
    "bcr_drug_barcode": "TCGA-D3-A1Q9-D35422",
    "bcr_drug_uuid": "A441C4EF-216C-4C22-8CD8-9A0F9774CDE8",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "GP-100",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 356,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 504,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "FBEE9FE7-8BED-41A6-BCFE-DE9F1BC80D01",
    "patient_ID": "TCGA.D3.A1QA",
    "bcr_drug_barcode": "TCGA-D3-A1QA-D32997",
    "bcr_drug_uuid": "22FADF39-8796-4EAB-87BE-92130E0783CA",
    "form_completion_date": "2012-10-2",
    "pharmaceutical_therapy_drug_name": "RECMAGE- A3",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 1485,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1538,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "DB239624-3DBA-48BB-9889-F479DC2BA046",
    "patient_ID": "TCGA.D3.A2JC",
    "bcr_drug_barcode": "TCGA-D3-A2JC-D34627",
    "bcr_drug_uuid": "D74F58ED-0EB4-4890-9200-7F6BA291ECDC",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALFA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 415,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3A27966B-2C4C-402F-B71B-DF7925C36A7C",
    "patient_ID": "TCGA.D3.A2JH",
    "bcr_drug_barcode": "TCGA-D3-A2JH-D34870",
    "bcr_drug_uuid": "16275EDF-75CC-441F-8C94-6C5E0CEC4E43",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 291,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "28CF244B-77DC-4B31-A65A-9746F15BB07E",
    "patient_ID": "TCGA.D3.A2JL",
    "bcr_drug_barcode": "TCGA-D3-A2JL-D34924",
    "bcr_drug_uuid": "C5C175AC-F5D7-454C-A99E-37AFB5A4E1BE",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "GP100",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 2552,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2911,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "28CF244B-77DC-4B31-A65A-9746F15BB07E",
    "patient_ID": "TCGA.D3.A2JL",
    "bcr_drug_barcode": "TCGA-D3-A2JL-D34927",
    "bcr_drug_uuid": "F8EB15E2-7BDE-4E1A-994D-95A408C77242",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "MAGE-3",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 2552,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2911,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "20AE4C90-EA2E-42E8-BC0E-F0E6BE0DADEB",
    "patient_ID": "TCGA.D3.A2JN",
    "bcr_drug_barcode": "TCGA-D3-A2JN-D35380",
    "bcr_drug_uuid": "5A640EFD-18CB-4F92-AF0B-BD5909512F7A",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON-ALFA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 123,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E9A42A85-9513-41B2-A71D-6D62F70B00E4",
    "patient_ID": "TCGA.D3.A2JP",
    "bcr_drug_barcode": "TCGA-D3-A2JP-D34981",
    "bcr_drug_uuid": "160686B9-7309-471D-BFA8-ADB8AC5C7D42",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 73,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 193,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2FF77467-19F8-45A0-8D42-2F9A69295498",
    "patient_ID": "TCGA.D3.A3C1",
    "bcr_drug_barcode": "TCGA-D3-A3C1-D35013",
    "bcr_drug_uuid": "BA946F88-CED9-4810-9A4E-4542333D9F39",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3B62E38C-D473-4329-86AB-5D4977F92B09",
    "patient_ID": "TCGA.D3.A3C7",
    "bcr_drug_barcode": "TCGA-D3-A3C7-D35021",
    "bcr_drug_uuid": "360C7D6E-7220-4201-AB31-C2D7136F3200",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 488,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B829885F-8681-4B00-B301-8B0E0C2C6684",
    "patient_ID": "TCGA.D3.A3CB",
    "bcr_drug_barcode": "TCGA-D3-A3CB-D35034",
    "bcr_drug_uuid": "4154979A-251D-4A20-A43F-8EA690A202B9",
    "form_completion_date": "2012-10-10",
    "pharmaceutical_therapy_drug_name": "MEL-44",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 2716,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3079,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "F581A9B5-8956-4AC3-9375-370C446CAD29",
    "patient_ID": "TCGA.D3.A3MV",
    "bcr_drug_barcode": "TCGA-D3-A3MV-D62508",
    "bcr_drug_uuid": "A09D03A1-7F23-47CA-9CF3-182364580770",
    "form_completion_date": "2014-7-18",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 572,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 639,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "963858B8-A8B6-498E-989A-271654713772",
    "patient_ID": "TCGA.D3.A51E",
    "bcr_drug_barcode": "TCGA-D3-A51E-D40982",
    "bcr_drug_uuid": "271D7904-A8BC-48CA-B8D4-A58916360347",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "ACTINOMYCIN-D",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2506,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2506,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "963858B8-A8B6-498E-989A-271654713772",
    "patient_ID": "TCGA.D3.A51E",
    "bcr_drug_barcode": "TCGA-D3-A51E-D40981",
    "bcr_drug_uuid": "EB610C14-F778-4869-B67A-BE410FA64332",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "MELPHALAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2506,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2506,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "44D176DB-2221-45A2-818B-EEF6832A51B6",
    "patient_ID": "TCGA.D3.A51G",
    "bcr_drug_barcode": "TCGA-D3-A51G-D40989",
    "bcr_drug_uuid": "79A61C3E-FC51-4563-99E0-B60316D6187E",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "MELPHALAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "44D176DB-2221-45A2-818B-EEF6832A51B6",
    "patient_ID": "TCGA.D3.A51G",
    "bcr_drug_barcode": "TCGA-D3-A51G-D40990",
    "bcr_drug_uuid": "A451E42C-4793-4296-9DBB-558D3767FD7D",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "ACTINOMYCIN-D",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "44D176DB-2221-45A2-818B-EEF6832A51B6",
    "patient_ID": "TCGA.D3.A51G",
    "bcr_drug_barcode": "TCGA-D3-A51G-D40991",
    "bcr_drug_uuid": "E2DA0838-5FD1-4398-8BA3-6DB451333E06",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "GP100",
    "pharmaceutical_therapy_type": "VACCINE",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "44D176DB-2221-45A2-818B-EEF6832A51B6",
    "patient_ID": "TCGA.D3.A51G",
    "bcr_drug_barcode": "TCGA-D3-A51G-D40993",
    "bcr_drug_uuid": "3C4F5E80-A872-4875-85FC-428059C054A8",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "RESIQUIMOD",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "50E4CDBC-B10B-4C6C-9981-68DEFA1A8FE0",
    "patient_ID": "TCGA.D3.A51H",
    "bcr_drug_barcode": "TCGA-D3-A51H-D41005",
    "bcr_drug_uuid": "B1A2E0A8-B6F8-4258-B9FA-CED9C63A87E9",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 894,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1045,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "50E4CDBC-B10B-4C6C-9981-68DEFA1A8FE0",
    "patient_ID": "TCGA.D3.A51H",
    "bcr_drug_barcode": "TCGA-D3-A51H-D41006",
    "bcr_drug_uuid": "5E6840F1-6465-468C-AB36-3E4B1DFB33EB",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "VINBLASTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 894,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1045,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "50E4CDBC-B10B-4C6C-9981-68DEFA1A8FE0",
    "patient_ID": "TCGA.D3.A51H",
    "bcr_drug_barcode": "TCGA-D3-A51H-D41007",
    "bcr_drug_uuid": "1827B56F-5FFA-4EAF-8725-9F8BC9567EDD",
    "form_completion_date": "2013-3-11",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 894,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1045,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6250B800-F72E-4C8E-A0E0-206049398BA7",
    "patient_ID": "TCGA.D3.A5GT",
    "bcr_drug_barcode": "TCGA-D3-A5GT-D43216",
    "bcr_drug_uuid": "BFF48717-818E-4159-AA4C-BD825DBCAA92",
    "form_completion_date": "2013-5-15",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 110,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4274D9AB-679F-453C-B086-7535CF798F0A",
    "patient_ID": "TCGA.D3.A8GB",
    "bcr_drug_barcode": "TCGA-D3-A8GB-D53565",
    "bcr_drug_uuid": "EFF7B87B-EAE2-4A32-90DD-C9DBD89C9B40",
    "form_completion_date": "2013-12-12",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 318,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6EC931E1-7A6F-47A8-8B30-F37271A50881",
    "patient_ID": "TCGA.D3.A8GK",
    "bcr_drug_barcode": "TCGA-D3-A8GK-D54525",
    "bcr_drug_uuid": "03C63A55-7198-4403-BD89-33FDBEA6693F",
    "form_completion_date": "2013-12-19",
    "pharmaceutical_therapy_drug_name": "MEL-44",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 2060,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2425,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7038DE05-4E26-49AF-B78A-5A00CE9A120B",
    "patient_ID": "TCGA.D3.A8GN",
    "bcr_drug_barcode": "TCGA-D3-A8GN-D54540",
    "bcr_drug_uuid": "E1E83843-377A-4D3A-A15A-6AF64A9F4084",
    "form_completion_date": "2013-12-19",
    "clinical_trial_drug_classification": "CANCERVAX",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1224,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1639,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "FED23055-1600-4128-8D73-E1AA902A9D1D",
    "patient_ID": "TCGA.D9.A148",
    "bcr_drug_barcode": "TCGA-D9-A148-D20725",
    "bcr_drug_uuid": "6425AFA1-E88F-4726-B334-F53AB7291629",
    "form_completion_date": "2012-1-19",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 4426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 4496,
    "drug_cycles": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "6993BC23-CD58-4761-BB77-3A3DCC2F7A1B",
    "patient_ID": "TCGA.DA.A1I1",
    "bcr_drug_barcode": "TCGA-DA-A1I1-D70083",
    "bcr_drug_uuid": "EA6537BB-5084-4FB4-BBE3-320FBC1809FE",
    "form_completion_date": "2015-1-29",
    "pharmaceutical_therapy_drug_name": "PEMBROLIZUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 6607,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A20AEAFC-9A68-4AF0-87EA-532EE835EBB2",
    "patient_ID": "TCGA.DA.A3F2",
    "bcr_drug_barcode": "TCGA-DA-A3F2-D70095",
    "bcr_drug_uuid": "F9793217-BAC0-429C-AE53-19B1A3061AB7",
    "form_completion_date": "2015-1-27",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 475,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 772,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "D8EAC750-9DAF-4465-B672-9E31FD369057",
    "patient_ID": "TCGA.DA.A3F5",
    "bcr_drug_barcode": "TCGA-DA-A3F5-D70098",
    "bcr_drug_uuid": "C93A647C-35B2-46B3-8D21-057387775391",
    "form_completion_date": "2015-1-27",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 6830,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 6869,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D8EAC750-9DAF-4465-B672-9E31FD369057",
    "patient_ID": "TCGA.DA.A3F5",
    "bcr_drug_barcode": "TCGA-DA-A3F5-D70099",
    "bcr_drug_uuid": "B57C37D6-D217-41C2-892B-023D2702F4A5",
    "form_completion_date": "2015-1-29",
    "pharmaceutical_therapy_drug_name": "PEMBROLIZUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 6660,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 6814,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D31689",
    "bcr_drug_uuid": "F2D08A97-93F5-4A06-BC1A-82A5F50E7DB1",
    "form_completion_date": "2012-5-8",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 203,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D31691",
    "bcr_drug_uuid": "C67513CB-4E3F-4EA2-871E-0E5AB079553B",
    "form_completion_date": "2012-5-8",
    "pharmaceutical_therapy_drug_name": "LAFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 203,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D31693",
    "bcr_drug_uuid": "1B4200F1-4F17-4A4A-8169-330F3C24DFB6",
    "form_completion_date": "2012-5-8",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 203,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D40313",
    "bcr_drug_uuid": "C7F4E13D-1D71-484F-8E93-D86DEA82598A",
    "form_completion_date": "2013-2-15",
    "pharmaceutical_therapy_drug_name": "TEMOZOLOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 547,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 632,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D40314",
    "bcr_drug_uuid": "656522F4-88F5-4C8C-B9F5-272929428ACE",
    "form_completion_date": "2013-2-15",
    "pharmaceutical_therapy_drug_name": "LAFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 505,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D40315",
    "bcr_drug_uuid": "839FDC5D-5D0E-453F-B8B8-3300CC5A1885",
    "form_completion_date": "2013-2-15",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 505,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F1BBE96-49D9-417B-BC9C-A09992489340",
    "patient_ID": "TCGA.EB.A24C",
    "bcr_drug_barcode": "TCGA-EB-A24C-D40316",
    "bcr_drug_uuid": "EB700B3F-B6E9-43D5-87D0-FA0310F6D5FA",
    "form_completion_date": "2013-2-15",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 505,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 517,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D7EE2693-39A8-4E3A-B6F6-E4729800E34E",
    "patient_ID": "TCGA.EB.A24D",
    "bcr_drug_barcode": "TCGA-EB-A24D-D31703",
    "bcr_drug_uuid": "CFE224F0-2C4C-488D-9B50-EE90838DBE9D",
    "form_completion_date": "2012-5-8",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 41,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D7EE2693-39A8-4E3A-B6F6-E4729800E34E",
    "patient_ID": "TCGA.EB.A24D",
    "bcr_drug_barcode": "TCGA-EB-A24D-D39572",
    "bcr_drug_uuid": "262A6121-77B2-41B2-9F8B-9563DBEB6C7C",
    "form_completion_date": "2013-1-25",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 645,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D7EE2693-39A8-4E3A-B6F6-E4729800E34E",
    "patient_ID": "TCGA.EB.A24D",
    "bcr_drug_barcode": "TCGA-EB-A24D-D39573",
    "bcr_drug_uuid": "9549BB9B-11DF-4A22-B54B-E3D8250CE569",
    "form_completion_date": "2013-1-25",
    "pharmaceutical_therapy_drug_name": "TEMODAL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 567,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 582,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D7EE2693-39A8-4E3A-B6F6-E4729800E34E",
    "patient_ID": "TCGA.EB.A24D",
    "bcr_drug_barcode": "TCGA-EB-A24D-D39575",
    "bcr_drug_uuid": "FDEEB651-E999-4547-ABDA-452BBC4CA0DE",
    "form_completion_date": "2013-1-25",
    "pharmaceutical_therapy_drug_name": "ALFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 525,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 645,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5226B25F-E326-4884-AF79-916E4BBB701F",
    "patient_ID": "TCGA.EB.A3XC",
    "bcr_drug_barcode": "TCGA-EB-A3XC-D53292",
    "bcr_drug_uuid": "69B2DD42-50A5-46BB-9334-690DCA9981D8",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 410,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 558,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8B93BDB4-B64B-4940-A814-F5B3F5AE56CC",
    "patient_ID": "TCGA.EB.A3Y6",
    "bcr_drug_barcode": "TCGA-EB-A3Y6-D48718",
    "bcr_drug_uuid": "B6189DEC-7891-431D-8FC1-6C94E38A1C15",
    "form_completion_date": "2013-9-19",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E2D8818-B377-45F5-97F4-F905DE22C487",
    "patient_ID": "TCGA.EB.A4OY",
    "bcr_drug_barcode": "TCGA-EB-A4OY-D57678",
    "bcr_drug_uuid": "1D2C877F-129D-4450-BB06-F8083F29D269",
    "form_completion_date": "2014-3-19",
    "pharmaceutical_therapy_drug_name": "FARESTON",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 593,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E2D8818-B377-45F5-97F4-F905DE22C487",
    "patient_ID": "TCGA.EB.A4OY",
    "bcr_drug_barcode": "TCGA-EB-A4OY-D57679",
    "bcr_drug_uuid": "B4CA0CDA-62F1-4958-9A87-142FBE04AEB8",
    "form_completion_date": "2014-3-19",
    "pharmaceutical_therapy_drug_name": "LOMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 593,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C757C326-6803-4451-A2D3-4368812855A7",
    "patient_ID": "TCGA.EB.A550",
    "bcr_drug_barcode": "TCGA-EB-A550-D57902",
    "bcr_drug_uuid": "559E24F9-7CBD-4562-BBAA-A9B2BA4713C7",
    "form_completion_date": "2014-4-1",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 6,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 264,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "960899ED-B61B-4B20-B16D-E37DFFB01AA3",
    "patient_ID": "TCGA.EB.A553",
    "bcr_drug_barcode": "TCGA-EB-A553-D51476",
    "bcr_drug_uuid": "03D7B471-967E-4F06-8BBA-736177847908",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 115,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "960899ED-B61B-4B20-B16D-E37DFFB01AA3",
    "patient_ID": "TCGA.EB.A553",
    "bcr_drug_barcode": "TCGA-EB-A553-D51478",
    "bcr_drug_uuid": "167F27BA-CD19-4162-9631-BB326EA96C32",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 115,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49918",
    "bcr_drug_uuid": "2F5F58F6-2C3E-4CFE-AF76-7A0D3DF97101",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49919",
    "bcr_drug_uuid": "4B936778-B6D3-4CDA-886F-19C0AF67DF4F",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "VINBLASTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49920",
    "bcr_drug_uuid": "EE02D679-0160-4712-BB4A-3F86C546A767",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "ZOFRAN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49921",
    "bcr_drug_uuid": "D298A479-C148-45D3-8839-B34372551942",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49922",
    "bcr_drug_uuid": "E7FC2055-7F70-431B-91BD-D974459FD778",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49923",
    "bcr_drug_uuid": "265C2EEA-FA05-462A-9598-AF6C79F5DEA4",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "ERYTHROPOIETIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49924",
    "bcr_drug_uuid": "294C8564-DE5C-4FC3-9FEE-EF9988C95177",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "CICLOSPORIN",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05F4058D-3066-4D16-8320-CF92F122945F",
    "patient_ID": "TCGA.EB.A57M",
    "bcr_drug_barcode": "TCGA-EB-A57M-D49925",
    "bcr_drug_uuid": "B420B3BF-54C1-41A1-B89B-CCD03D217BCB",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "RENAMIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2E6F9985-6D13-4B08-8A40-5EA44E9553F0",
    "patient_ID": "TCGA.EB.A5FP",
    "bcr_drug_barcode": "TCGA-EB-A5FP-D56485",
    "bcr_drug_uuid": "F8885A2A-715B-4A8C-9540-D0F93518A4BD",
    "form_completion_date": "2014-2-10",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 52,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2E6F9985-6D13-4B08-8A40-5EA44E9553F0",
    "patient_ID": "TCGA.EB.A5FP",
    "bcr_drug_barcode": "TCGA-EB-A5FP-D56486",
    "bcr_drug_uuid": "375F46B1-DD5B-4A32-A44B-23173C2A5C0C",
    "form_completion_date": "2014-2-10",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 52,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0EB0B477-1C7A-4416-895A-EA6463DBE847",
    "patient_ID": "TCGA.EB.A5KH",
    "bcr_drug_barcode": "TCGA-EB-A5KH-D51003",
    "bcr_drug_uuid": "EF692434-8B47-4DE8-B334-EAE51D25D88F",
    "form_completion_date": "2013-11-5",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 557,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 615,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0EB0B477-1C7A-4416-895A-EA6463DBE847",
    "patient_ID": "TCGA.EB.A5KH",
    "bcr_drug_barcode": "TCGA-EB-A5KH-D51004",
    "bcr_drug_uuid": "D8333D42-D4F5-42F4-9854-A73C1AF1368B",
    "form_completion_date": "2013-11-5",
    "pharmaceutical_therapy_drug_name": "VINBLASTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 557,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 615,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0EB0B477-1C7A-4416-895A-EA6463DBE847",
    "patient_ID": "TCGA.EB.A5KH",
    "bcr_drug_barcode": "TCGA-EB-A5KH-D51007",
    "bcr_drug_uuid": "E357E722-254F-48E5-AA19-948FEBEEB45A",
    "form_completion_date": "2013-11-5",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 557,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 615,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0EB0B477-1C7A-4416-895A-EA6463DBE847",
    "patient_ID": "TCGA.EB.A5KH",
    "bcr_drug_barcode": "TCGA-EB-A5KH-D51009",
    "bcr_drug_uuid": "7111438A-B4F8-488D-8C88-C2E3855D37A7",
    "form_completion_date": "2013-11-5",
    "pharmaceutical_therapy_drug_name": "LEUKINE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 557,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 615,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA597E8B-7813-4837-B778-4DAFE3B091BB",
    "patient_ID": "TCGA.EB.A5SH",
    "bcr_drug_barcode": "TCGA-EB-A5SH-D63496",
    "bcr_drug_uuid": "E70456D7-5430-4EE5-9851-56DA11371D2F",
    "form_completion_date": "2014-8-11",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1091,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA597E8B-7813-4837-B778-4DAFE3B091BB",
    "patient_ID": "TCGA.EB.A5SH",
    "bcr_drug_barcode": "TCGA-EB-A5SH-D63497",
    "bcr_drug_uuid": "6CB72320-3FDF-49E8-8F34-C664D257AC87",
    "form_completion_date": "2014-8-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1091,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA597E8B-7813-4837-B778-4DAFE3B091BB",
    "patient_ID": "TCGA.EB.A5SH",
    "bcr_drug_barcode": "TCGA-EB-A5SH-D63499",
    "bcr_drug_uuid": "6D740B57-728E-4088-8903-A7CF2ED3A687",
    "form_completion_date": "2014-8-11",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1154,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1217,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F5F42370-9974-4375-B338-5F68BB0C3958",
    "patient_ID": "TCGA.EB.A5UL",
    "bcr_drug_barcode": "TCGA-EB-A5UL-D56488",
    "bcr_drug_uuid": "74263AA6-4C3A-4A11-B704-EA3D080C9874",
    "form_completion_date": "2014-2-10",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 140,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 280,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F5F42370-9974-4375-B338-5F68BB0C3958",
    "patient_ID": "TCGA.EB.A5UL",
    "bcr_drug_barcode": "TCGA-EB-A5UL-D56489",
    "bcr_drug_uuid": "97C9D614-1F6D-43A2-A996-4E11AA49F9ED",
    "form_completion_date": "2014-2-10",
    "pharmaceutical_therapy_drug_name": "VINBLASTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 140,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 280,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F5F42370-9974-4375-B338-5F68BB0C3958",
    "patient_ID": "TCGA.EB.A5UL",
    "bcr_drug_barcode": "TCGA-EB-A5UL-D56490",
    "bcr_drug_uuid": "6479F494-4E76-4E18-859A-6DB0688256FF",
    "form_completion_date": "2014-2-10",
    "pharmaceutical_therapy_drug_name": "BLEOMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 140,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 280,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "82E85AC9-8E3E-4C2E-AE0B-A32CEEB8115D",
    "patient_ID": "TCGA.EB.A6QY",
    "bcr_drug_barcode": "TCGA-EB-A6QY-D57710",
    "bcr_drug_uuid": "DF7DB810-BA7C-4477-A02C-30AD8505D5BF",
    "form_completion_date": "2014-3-21",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 192,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "82E85AC9-8E3E-4C2E-AE0B-A32CEEB8115D",
    "patient_ID": "TCGA.EB.A6QY",
    "bcr_drug_barcode": "TCGA-EB-A6QY-D57711",
    "bcr_drug_uuid": "BEDB2A67-17E6-4B73-BAB6-8407535AC306",
    "form_completion_date": "2014-3-21",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 192,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "82E85AC9-8E3E-4C2E-AE0B-A32CEEB8115D",
    "patient_ID": "TCGA.EB.A6QY",
    "bcr_drug_barcode": "TCGA-EB-A6QY-D57712",
    "bcr_drug_uuid": "54D415E8-AF68-468D-98C2-E615BA28D9CE",
    "form_completion_date": "2014-3-21",
    "pharmaceutical_therapy_drug_name": "LAFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 210,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 218,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "800F3039-97E0-441E-8292-4CCF1BB4797A",
    "patient_ID": "TCGA.EB.A6QZ",
    "bcr_drug_barcode": "TCGA-EB-A6QZ-D58784",
    "bcr_drug_uuid": "DB6755F9-6D31-4854-BFA8-C114DB48FA89",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 153,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 244,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "800F3039-97E0-441E-8292-4CCF1BB4797A",
    "patient_ID": "TCGA.EB.A6QZ",
    "bcr_drug_barcode": "TCGA-EB-A6QZ-D60719",
    "bcr_drug_uuid": "605A2A10-34C1-441D-9204-423B124EADCC",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "VINCRISTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 153,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 244,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5BF40B29-D722-430A-91BC-CAD941EE3694",
    "patient_ID": "TCGA.EB.A6R0",
    "bcr_drug_barcode": "TCGA-EB-A6R0-D57914",
    "bcr_drug_uuid": "210DEFBD-E099-4B52-AD8A-64D8CB9DE0D3",
    "form_completion_date": "2014-3-28",
    "pharmaceutical_therapy_drug_name": "LOMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 19,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EE08EDA6-033E-403B-A26A-747B118AE897",
    "patient_ID": "TCGA.EB.A85J",
    "bcr_drug_barcode": "TCGA-EB-A85J-D61879",
    "bcr_drug_uuid": "40D2E43A-C9F4-4DF8-9BA2-A3822FF2FD1A",
    "form_completion_date": "2014-7-9",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 13,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EE08EDA6-033E-403B-A26A-747B118AE897",
    "patient_ID": "TCGA.EB.A85J",
    "bcr_drug_barcode": "TCGA-EB-A85J-D61890",
    "bcr_drug_uuid": "87EFDA20-155F-42FA-9A1C-9FA06BC7B267",
    "form_completion_date": "2014-7-9",
    "pharmaceutical_therapy_drug_name": "VINCRISTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 13,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "714B4003-959A-47D5-8912-A250B90D7CD4",
    "patient_ID": "TCGA.EE.A182",
    "bcr_drug_barcode": "TCGA-EE-A182-D49738",
    "bcr_drug_uuid": "FA04F917-E799-4B40-A120-DCF3CBA050C1",
    "form_completion_date": "2013-10-9",
    "pharmaceutical_therapy_drug_name": "PV-10",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 329,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 329,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A01A350D-64BE-4AF3-91C3-7D681C3DB11D",
    "patient_ID": "TCGA.EE.A185",
    "bcr_drug_barcode": "TCGA-EE-A185-D49739",
    "bcr_drug_uuid": "108A678F-5BC0-4735-984D-EAC14C7B91B0",
    "form_completion_date": "2013-10-9",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51",
    "patient_ID": "TCGA.EE.A29C",
    "bcr_drug_barcode": "TCGA-EE-A29C-D59902",
    "bcr_drug_uuid": "592FD4C1-37D3-4F45-9FB4-798D59E7051F",
    "form_completion_date": "2014-5-22",
    "pharmaceutical_therapy_drug_name": "PACLITAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 439,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 620,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51",
    "patient_ID": "TCGA.EE.A29C",
    "bcr_drug_barcode": "TCGA-EE-A29C-D59903",
    "bcr_drug_uuid": "F9B42ED5-1FB0-42B7-B5D1-E93E4FC27EE5",
    "form_completion_date": "2014-5-22",
    "pharmaceutical_therapy_drug_name": "GSK BRAF INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1114,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1502,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51",
    "patient_ID": "TCGA.EE.A29C",
    "bcr_drug_barcode": "TCGA-EE-A29C-D65639",
    "bcr_drug_uuid": "8CF1E4C0-8CD8-497F-9B12-31549514175F",
    "form_completion_date": "2014-9-26",
    "pharmaceutical_therapy_drug_name": "YERVOY",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1500,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1623,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51",
    "patient_ID": "TCGA.EE.A29C",
    "bcr_drug_barcode": "TCGA-EE-A29C-D65640",
    "bcr_drug_uuid": "71EE9B6E-39C6-49C4-ABDA-742B2372BDB4",
    "form_completion_date": "2014-9-26",
    "pharmaceutical_therapy_drug_name": "DABRAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2262,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2413,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FC5B5D2F-0D03-45C2-B7A0-BA6EC108FE51",
    "patient_ID": "TCGA.EE.A29C",
    "bcr_drug_barcode": "TCGA-EE-A29C-D68734",
    "bcr_drug_uuid": "ED7938C2-23C8-4CC7-A1EE-0194D139C83C",
    "form_completion_date": "2014-12-15",
    "pharmaceutical_therapy_drug_name": "TRAMETINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2262,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2413,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C8BA1856-D055-4DC6-A184-72763C76AAE4",
    "patient_ID": "TCGA.EE.A29H",
    "bcr_drug_barcode": "TCGA-EE-A29H-D45082",
    "bcr_drug_uuid": "6C4574D2-1174-413E-AAF7-1FE2D59E89FE",
    "form_completion_date": "2013-7-31",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 895,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "C8BA1856-D055-4DC6-A184-72763C76AAE4",
    "patient_ID": "TCGA.EE.A29H",
    "bcr_drug_barcode": "TCGA-EE-A29H-D55041",
    "bcr_drug_uuid": "7F5CD97D-210E-4280-8B17-A1083D4ED54F",
    "form_completion_date": "2013-12-26",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 895,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1231,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "C8BA1856-D055-4DC6-A184-72763C76AAE4",
    "patient_ID": "TCGA.EE.A29H",
    "bcr_drug_barcode": "TCGA-EE-A29H-D55042",
    "bcr_drug_uuid": "3878F661-D2D2-4EF3-A6FC-8AAF96AFC114",
    "form_completion_date": "2013-12-26",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1294,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6A1818F9-9303-41B0-B3B7-07FAF5055C86",
    "patient_ID": "TCGA.EE.A29Q",
    "bcr_drug_barcode": "TCGA-EE-A29Q-D55046",
    "bcr_drug_uuid": "42291B0A-AB03-4AF8-926A-05B66EB1354C",
    "form_completion_date": "2013-12-27",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1837,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1858,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9B99FFEE-FE9F-4BE5-A00A-EF86627282A4",
    "patient_ID": "TCGA.EE.A29T",
    "bcr_drug_barcode": "TCGA-EE-A29T-D55118",
    "bcr_drug_uuid": "DB669D12-291E-434D-B9E8-65993F9E2A1B",
    "form_completion_date": "2013-12-29",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 11015,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "01CB0004-FC1E-4DA5-9D27-F458F8D711EE",
    "patient_ID": "TCGA.EE.A29V",
    "bcr_drug_barcode": "TCGA-EE-A29V-D45165",
    "bcr_drug_uuid": "1A0E97AB-0953-45E7-9511-631C5BF5096E",
    "form_completion_date": "2013-7-9",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 715,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 787,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "26293554-04D3-4FC9-B12E-6A199278ED11",
    "patient_ID": "TCGA.EE.A29X",
    "bcr_drug_barcode": "TCGA-EE-A29X-D45274",
    "bcr_drug_uuid": "238C5DFA-FA04-47A7-A394-8934975D6053",
    "form_completion_date": "2013-7-11",
    "pharmaceutical_therapy_drug_name": "FOTEMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 517,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 517,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "865128C9-2E8E-4683-9232-174282AE984D",
    "patient_ID": "TCGA.EE.A2A5",
    "bcr_drug_barcode": "TCGA-EE-A2A5-D45370",
    "bcr_drug_uuid": "468B82AE-D647-457E-89A8-1F52CC01D3C8",
    "form_completion_date": "2013-7-11",
    "pharmaceutical_therapy_drug_name": "FOTEMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1142,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1142,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "913F21A9-F727-4983-AB3A-61B5B3FC7F5E",
    "patient_ID": "TCGA.EE.A2GH",
    "bcr_drug_barcode": "TCGA-EE-A2GH-D45427",
    "bcr_drug_uuid": "039D647F-6EAC-4FC3-BF71-3AFDFA53B21B",
    "form_completion_date": "2013-7-31",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 4948,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "913F21A9-F727-4983-AB3A-61B5B3FC7F5E",
    "patient_ID": "TCGA.EE.A2GH",
    "bcr_drug_barcode": "TCGA-EE-A2GH-D55131",
    "bcr_drug_uuid": "DAED1221-3197-4637-9D27-37AF94175588",
    "form_completion_date": "2013-12-29",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 4948,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 5753,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B4079A49-BB11-430A-9A1E-19BD46D87FBE",
    "patient_ID": "TCGA.EE.A2GI",
    "bcr_drug_barcode": "TCGA-EE-A2GI-D45429",
    "bcr_drug_uuid": "7A66FCAF-ADE2-4434-B2B4-A7B964D48E6A",
    "form_completion_date": "2013-7-31",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 642,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B4079A49-BB11-430A-9A1E-19BD46D87FBE",
    "patient_ID": "TCGA.EE.A2GI",
    "bcr_drug_barcode": "TCGA-EE-A2GI-D55133",
    "bcr_drug_uuid": "F43FC435-FB99-4109-8909-AD265202FEF9",
    "form_completion_date": "2013-12-29",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 642,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1393,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "9C0240D6-8B75-41AE-8FE8-269831FD1E41",
    "patient_ID": "TCGA.EE.A2GL",
    "bcr_drug_barcode": "TCGA-EE-A2GL-D45433",
    "bcr_drug_uuid": "BD858B95-F984-4F47-AE04-1DF7FE800FC0",
    "form_completion_date": "2013-7-31",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 1421,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "9C0240D6-8B75-41AE-8FE8-269831FD1E41",
    "patient_ID": "TCGA.EE.A2GL",
    "bcr_drug_barcode": "TCGA-EE-A2GL-D55197",
    "bcr_drug_uuid": "C99A5B28-B438-4B29-B43A-1C3C3F265EEA",
    "form_completion_date": "2013-12-30",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 1421,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2093,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "880BB701-F1D3-4BF2-BFC8-143AD8D07B6A",
    "patient_ID": "TCGA.EE.A2GS",
    "bcr_drug_barcode": "TCGA-EE-A2GS-D59676",
    "bcr_drug_uuid": "3AB0B595-ABB7-4F0A-8874-65FCA35E36BC",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "DABRAFENIB",
    "clinical_trial_drug_classification": "BRAF INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1596,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1978,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "880BB701-F1D3-4BF2-BFC8-143AD8D07B6A",
    "patient_ID": "TCGA.EE.A2GS",
    "bcr_drug_barcode": "TCGA-EE-A2GS-D59679",
    "bcr_drug_uuid": "E407CD8E-90B5-4F51-A238-896EC472A58C",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1979,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2075,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "880BB701-F1D3-4BF2-BFC8-143AD8D07B6A",
    "patient_ID": "TCGA.EE.A2GS",
    "bcr_drug_barcode": "TCGA-EE-A2GS-D59680",
    "bcr_drug_uuid": "F356C42E-2ED9-4BB7-B7FC-9B4548A6B7A2",
    "form_completion_date": "2014-5-20",
    "clinical_trial_drug_classification": "MULTI-KINASE INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2127,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "880BB701-F1D3-4BF2-BFC8-143AD8D07B6A",
    "patient_ID": "TCGA.EE.A2GS",
    "bcr_drug_barcode": "TCGA-EE-A2GS-D59682",
    "bcr_drug_uuid": "AC62CF2D-0A71-400C-90B9-58B0DB53346B",
    "form_completion_date": "2014-5-20",
    "clinical_trial_drug_classification": "BRAF AND MEK INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2257,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2354,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "880BB701-F1D3-4BF2-BFC8-143AD8D07B6A",
    "patient_ID": "TCGA.EE.A2GS",
    "bcr_drug_barcode": "TCGA-EE-A2GS-D59683",
    "bcr_drug_uuid": "51B722AA-2F6A-4BC0-8A5A-0764CF606D73",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2372,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "24FAA36A-268D-4A13-B3AE-EACD431A2BCC",
    "patient_ID": "TCGA.EE.A2GU",
    "bcr_drug_barcode": "TCGA-EE-A2GU-D45477",
    "bcr_drug_uuid": "93A12D02-CF70-4DA3-B988-1A6FE2704114",
    "form_completion_date": "2013-7-31",
    "clinical_trial_drug_classification": "MAGE A3 VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 1855,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2609,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B5E37B9B-6264-4CC8-9B44-1D8AC0692D6C",
    "patient_ID": "TCGA.EE.A2M5",
    "bcr_drug_barcode": "TCGA-EE-A2M5-D46109",
    "bcr_drug_uuid": "B4E58FE1-8315-4F3B-989E-5AE298B9BD10",
    "form_completion_date": "2013-8-1",
    "pharmaceutical_therapy_drug_name": "PNU-159548",
    "clinical_trial_drug_classification": "CHEMOTHERAPY",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 559,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "58F0AE89-E277-4DFF-BB73-777CDF602DC7",
    "patient_ID": "TCGA.EE.A2M6",
    "bcr_drug_barcode": "TCGA-EE-A2M6-D46374",
    "bcr_drug_uuid": "AE474079-730C-4072-8E8B-CD9EC4524BE1",
    "form_completion_date": "2013-8-7",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 992,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2763,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "D28B2D64-2399-4CE1-9C9A-7538DABAB862",
    "patient_ID": "TCGA.EE.A2MD",
    "bcr_drug_barcode": "TCGA-EE-A2MD-D46560",
    "bcr_drug_uuid": "2F37EDE4-3256-43C1-A7CF-48488B0B027B",
    "form_completion_date": "2013-8-8",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1377,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1408,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D70E0D27-7F27-4807-A36E-9FB7B00F0A70",
    "patient_ID": "TCGA.EE.A2ME",
    "bcr_drug_barcode": "TCGA-EE-A2ME-D49800",
    "bcr_drug_uuid": "7C12FEEF-91B4-4C80-A850-EDA4143E99D1",
    "form_completion_date": "2013-10-10",
    "pharmaceutical_therapy_drug_name": "CANCER VAX",
    "clinical_trial_drug_classification": "CANCER VAX",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 2296,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2933,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "E653F888-37CF-41D5-A1CF-45397C90B31D",
    "patient_ID": "TCGA.EE.A2MG",
    "bcr_drug_barcode": "TCGA-EE-A2MG-D49801",
    "bcr_drug_uuid": "2F8271BB-050C-4F42-A026-B11E15F49FA0",
    "form_completion_date": "2013-10-10",
    "pharmaceutical_therapy_drug_name": "CANCER VAX",
    "clinical_trial_drug_classification": "CANCER VAX",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 1837,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2585,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "E653F888-37CF-41D5-A1CF-45397C90B31D",
    "patient_ID": "TCGA.EE.A2MG",
    "bcr_drug_barcode": "TCGA-EE-A2MG-D49802",
    "bcr_drug_uuid": "738B0161-28C3-429B-ADB9-B8FDE4107DFE",
    "form_completion_date": "2013-10-10",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2764,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2932,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BD2345ED-33B8-4010-8479-4D6C67E29561",
    "patient_ID": "TCGA.EE.A2MH",
    "bcr_drug_barcode": "TCGA-EE-A2MH-D45169",
    "bcr_drug_uuid": "178F732A-37B0-4784-BF47-AC1E884B98FC",
    "form_completion_date": "2013-7-9",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 356,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 429,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "01CFBFAE-F344-439D-AEAB-A9E15D636325",
    "patient_ID": "TCGA.EE.A2ML",
    "bcr_drug_barcode": "TCGA-EE-A2ML-D59747",
    "bcr_drug_uuid": "D59E75DB-7F98-4A9B-911D-2FD63B98F034",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "clinical_trial_drug_classification": "CHEMOTHERAPY",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 5973,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 6156,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "01CFBFAE-F344-439D-AEAB-A9E15D636325",
    "patient_ID": "TCGA.EE.A2ML",
    "bcr_drug_barcode": "TCGA-EE-A2ML-D59748",
    "bcr_drug_uuid": "FE3FA6A8-83D4-4DBD-9928-5950DD881AD0",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "FOTEMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 6279,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 6339,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "01CFBFAE-F344-439D-AEAB-A9E15D636325",
    "patient_ID": "TCGA.EE.A2ML",
    "bcr_drug_barcode": "TCGA-EE-A2ML-D59749",
    "bcr_drug_uuid": "9325A255-5031-40AF-AB42-FB9A9726F22B",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "MORAB-004",
    "clinical_trial_drug_classification": "IMMUNOTHERAPY",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 6355,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 6440,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "C9DEA107-FC12-4559-AD27-2800AE6B42E4",
    "patient_ID": "TCGA.EE.A2MM",
    "bcr_drug_barcode": "TCGA-EE-A2MM-D49869",
    "bcr_drug_uuid": "F33FFC7C-D7E4-41B4-ACE0-F07A25F07DC8",
    "form_completion_date": "2013-10-13",
    "pharmaceutical_therapy_drug_name": "VMCL",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 3636,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 4328,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C9DEA107-FC12-4559-AD27-2800AE6B42E4",
    "patient_ID": "TCGA.EE.A2MM",
    "bcr_drug_barcode": "TCGA-EE-A2MM-D49870",
    "bcr_drug_uuid": "BEEC3CD8-ED73-499C-ABD0-4FD852B361DE",
    "form_completion_date": "2013-10-13",
    "pharmaceutical_therapy_drug_name": "AUTOLOGOUS VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 4412,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 4618,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0797CAAF-18AD-41C6-820A-E96554D14B31",
    "patient_ID": "TCGA.EE.A2MN",
    "bcr_drug_barcode": "TCGA-EE-A2MN-D49879",
    "bcr_drug_uuid": "75608E15-565C-4D1E-9D33-29498AB5D639",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "DACABARZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1290,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1338,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C127FFB6-2CCF-4E90-B811-0AA40EBFAB17",
    "patient_ID": "TCGA.EE.A2MQ",
    "bcr_drug_barcode": "TCGA-EE-A2MQ-D49927",
    "bcr_drug_uuid": "2180FF50-2FA8-403E-B5C6-6BB357B8806A",
    "form_completion_date": "2013-10-15",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1176,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1207,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA55097F-4FD6-45E7-A394-F4122CEAFC51",
    "patient_ID": "TCGA.EE.A3AA",
    "bcr_drug_barcode": "TCGA-EE-A3AA-D49303",
    "bcr_drug_uuid": "9207B02C-F94F-43B4-9113-2534BAEA7952",
    "form_completion_date": "2013-9-30",
    "clinical_trial_drug_classification": "CANCER VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0F1FB775-C4A2-4A1E-8B09-F935233CDAEE",
    "patient_ID": "TCGA.EE.A3AD",
    "bcr_drug_barcode": "TCGA-EE-A3AD-D55196",
    "bcr_drug_uuid": "7BA46207-8053-4C9C-A381-2F2DFF3C4894",
    "form_completion_date": "2014-5-21",
    "pharmaceutical_therapy_drug_name": "BRAF INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 632,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE"
  },
  {
    "bcr_patient_uuid": "93A31E9F-6557-4F15-A49F-5DFEA2C588B2",
    "patient_ID": "TCGA.EE.A3AE",
    "bcr_drug_barcode": "TCGA-EE-A3AE-D49934",
    "bcr_drug_uuid": "BC86C2A9-2D1A-44D6-B9B1-E673AFF8913D",
    "form_completion_date": "2013-10-15",
    "pharmaceutical_therapy_drug_name": "MAGE A3",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 804,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1574,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "015BA831-106B-4B84-9E8C-243A9EEEEBF6",
    "patient_ID": "TCGA.EE.A3AF",
    "bcr_drug_barcode": "TCGA-EE-A3AF-D49565",
    "bcr_drug_uuid": "7549637E-4237-459B-8A8E-BF8EB2B931F3",
    "form_completion_date": "2013-10-4",
    "pharmaceutical_therapy_drug_name": "FOTEMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 384,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 404,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F09F3062-F904-4AFF-9CD6-38EED201E652",
    "patient_ID": "TCGA.EE.A3AG",
    "bcr_drug_barcode": "TCGA-EE-A3AG-D59765",
    "bcr_drug_uuid": "972670C7-1733-4012-82F1-148808A5EC8C",
    "form_completion_date": "2014-5-20",
    "clinical_trial_drug_classification": "BRAF INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 741,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "F09F3062-F904-4AFF-9CD6-38EED201E652",
    "patient_ID": "TCGA.EE.A3AG",
    "bcr_drug_barcode": "TCGA-EE-A3AG-D59766",
    "bcr_drug_uuid": "DA833466-EBEC-45C6-8B80-9490930C6B04",
    "form_completion_date": "2014-5-20",
    "clinical_trial_drug_classification": "MEK INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 741,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "92D79156-9139-487B-8582-CE0E87B4ECD0",
    "patient_ID": "TCGA.EE.A3AH",
    "bcr_drug_barcode": "TCGA-EE-A3AH-D50105",
    "bcr_drug_uuid": "0F0B5AAF-1D31-4330-95DD-71853276402F",
    "form_completion_date": "2013-10-15",
    "pharmaceutical_therapy_drug_name": "PI88",
    "clinical_trial_drug_classification": "CHEMOTHERAPY",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3977,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 4104,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "6E1040D2-DEE0-43C9-8462-FC0859D7D2AF",
    "patient_ID": "TCGA.EE.A3JB",
    "bcr_drug_barcode": "TCGA-EE-A3JB-D59760",
    "bcr_drug_uuid": "CAF27AF1-9FCE-402C-B211-7D5176C31A6B",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "ALKERAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 24,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "296F44F9-3ECB-4B40-AE51-C3A06E3FBE00",
    "patient_ID": "TCGA.EE.A3JI",
    "bcr_drug_barcode": "TCGA-EE-A3JI-D59754",
    "bcr_drug_uuid": "A2BFB1F4-4C5F-49BD-9C72-1EDD7311422D",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 4529,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 4571,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "296F44F9-3ECB-4B40-AE51-C3A06E3FBE00",
    "patient_ID": "TCGA.EE.A3JI",
    "bcr_drug_barcode": "TCGA-EE-A3JI-D59755",
    "bcr_drug_uuid": "E1A09352-5F0F-43B4-9C09-DDBE436D1BA4",
    "form_completion_date": "2014-5-20",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 4608,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "51B4E55C-5307-4A13-9B2A-FBD58575335E",
    "patient_ID": "TCGA.ER.A195",
    "bcr_drug_barcode": "TCGA-ER-A195-D30490",
    "bcr_drug_uuid": "F503B89F-0B5D-4F29-96E8-FF5F09E46F59",
    "form_completion_date": "2012-4-11",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 562,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 911,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "EA240769-E51C-45F5-A131-BA123E598622",
    "patient_ID": "TCGA.ER.A198",
    "bcr_drug_barcode": "TCGA-ER-A198-D30608",
    "bcr_drug_uuid": "2E9E4483-EC3E-443E-8E0E-FF50D3FB71F3",
    "form_completion_date": "2012-4-13",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 517,
    "drug_units": "MG",
    "drug_dose": 400,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3FEA3F02-2DB3-44E0-984E-C61130D92C9B",
    "patient_ID": "TCGA.ER.A19E",
    "bcr_drug_barcode": "TCGA-ER-A19E-D30890",
    "bcr_drug_uuid": "29EE1CB8-C41E-4CCE-B7E2-C494BECF63EF",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "PACLITAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 230,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 257,
    "drug_cycles": 2,
    "regimen_number": 6,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "3FEA3F02-2DB3-44E0-984E-C61130D92C9B",
    "patient_ID": "TCGA.ER.A19E",
    "bcr_drug_barcode": "TCGA-ER-A19E-D30892",
    "bcr_drug_uuid": "922B5458-0380-42A4-9E49-4EBFBAE78EEF",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 230,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 257,
    "drug_cycles": 2,
    "regimen_number": 6,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "90AA7540-93E7-4FFA-9E77-879198BE1E7B",
    "patient_ID": "TCGA.ER.A19G",
    "bcr_drug_barcode": "TCGA-ER-A19G-D30920",
    "bcr_drug_uuid": "142F24C0-60F7-4833-B857-F5DA091F7AF6",
    "form_completion_date": "2012-4-19",
    "pharmaceutical_therapy_drug_name": "GM-CSF",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 4740,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 5013,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "E11A109D-31CB-40F7-AA17-50797B287A4F",
    "patient_ID": "TCGA.ER.A19H",
    "bcr_drug_barcode": "TCGA-ER-A19H-D30922",
    "bcr_drug_uuid": "679F866C-F037-48BF-920B-C8E369748BE3",
    "form_completion_date": "2012-4-19",
    "pharmaceutical_therapy_drug_name": "PATRIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3716,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "E11A109D-31CB-40F7-AA17-50797B287A4F",
    "patient_ID": "TCGA.ER.A19H",
    "bcr_drug_barcode": "TCGA-ER-A19H-D32359",
    "bcr_drug_uuid": "D9F6730E-185D-4B1E-BF87-98D3E5885262",
    "form_completion_date": "2012-5-24",
    "pharmaceutical_therapy_drug_name": "DTIC",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3627,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3716,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CE28F65D-4AE8-4E63-815F-5B8D4389E092",
    "patient_ID": "TCGA.ER.A19J",
    "bcr_drug_barcode": "TCGA-ER-A19J-D30929",
    "bcr_drug_uuid": "DF2E59F1-35BF-4579-A704-69A87AA266C8",
    "form_completion_date": "2012-4-19",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 119,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 119,
    "drug_cycles": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "F9E36BC2-484F-48E8-82BA-99026957277A",
    "patient_ID": "TCGA.ER.A19K",
    "bcr_drug_barcode": "TCGA-ER-A19K-D30933",
    "bcr_drug_uuid": "78997F9D-2144-4DA8-B403-88C737AC0988",
    "form_completion_date": "2012-4-19",
    "pharmaceutical_therapy_drug_name": "TEMOZOLOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 388,
    "drug_cycles": 2,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "7A918706-C697-4CEF-9661-346C5A612FF8",
    "patient_ID": "TCGA.ER.A19M",
    "bcr_drug_barcode": "TCGA-ER-A19M-D33562",
    "bcr_drug_uuid": "8905B3C5-3484-4A73-B08F-B26CB937FD3B",
    "form_completion_date": "2012-7-6",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1019,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1093,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9EE83669-D7A4-476E-8857-304600B4917A",
    "patient_ID": "TCGA.ER.A19N",
    "bcr_drug_barcode": "TCGA-ER-A19N-D30980",
    "bcr_drug_uuid": "25E5E0DB-CF2A-493F-BF20-5311040C2675",
    "form_completion_date": "2012-4-20",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 4,
    "drug_dose": 20,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "69C0EF46-3117-46F3-B36E-581EB03EB829",
    "patient_ID": "TCGA.ER.A19O",
    "bcr_drug_barcode": "TCGA-ER-A19O-D30988",
    "bcr_drug_uuid": "C22CD1E3-9363-4C1E-A8E0-69F49DEDB8DA",
    "form_completion_date": "2012-4-20",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 154,
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "391EAB51-B140-4BC2-BC8C-99400FBA9066",
    "patient_ID": "TCGA.ER.A19Q",
    "bcr_drug_barcode": "TCGA-ER-A19Q-D31037",
    "bcr_drug_uuid": "04BD496F-995A-4979-80B9-E6C939FFDEFD",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "IL-18",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1274,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1337,
    "drug_cycles": 2,
    "drug_units": "MG/KG",
    "drug_dose": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "391EAB51-B140-4BC2-BC8C-99400FBA9066",
    "patient_ID": "TCGA.ER.A19Q",
    "bcr_drug_barcode": "TCGA-ER-A19Q-D31038",
    "bcr_drug_uuid": "4D004A62-3BEC-4A66-8F86-19793CB28CFD",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1394,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1428,
    "drug_cycles": 1,
    "drug_units": "G/DAY",
    "drug_dose": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "1251ACEE-CEB4-4530-BA5B-4D163FCAB8D2",
    "patient_ID": "TCGA.ER.A1A1",
    "bcr_drug_barcode": "TCGA-ER-A1A1-D31066",
    "bcr_drug_uuid": "5CE241B9-0730-40AE-81EC-5E4D2EC2FF7D",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 84,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 418,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "B9607824-A8D3-4915-AB73-962CDCFD8DC3",
    "patient_ID": "TCGA.ER.A2NC",
    "bcr_drug_barcode": "TCGA-ER-A2NC-D31280",
    "bcr_drug_uuid": "FEE9680A-05DE-4011-898D-93FF8DC7580B",
    "form_completion_date": "2012-4-26",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1278,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "D32A4219-4CCA-470F-B6B3-11447D9F5E0B",
    "patient_ID": "TCGA.ER.A2NF",
    "bcr_drug_barcode": "TCGA-ER-A2NF-D31344",
    "bcr_drug_uuid": "78720D1C-5C09-4DA0-A444-0B7CC6684F70",
    "form_completion_date": "2012-4-30",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 120,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 136,
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "D32A4219-4CCA-470F-B6B3-11447D9F5E0B",
    "patient_ID": "TCGA.ER.A2NF",
    "bcr_drug_barcode": "TCGA-ER-A2NF-D31345",
    "bcr_drug_uuid": "93694460-ED92-4DF7-B8B2-D6A6769A680C",
    "form_completion_date": "2012-4-30",
    "pharmaceutical_therapy_drug_name": "IL-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 471,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 502,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "D32A4219-4CCA-470F-B6B3-11447D9F5E0B",
    "patient_ID": "TCGA.ER.A2NF",
    "bcr_drug_barcode": "TCGA-ER-A2NF-D31346",
    "bcr_drug_uuid": "C235537F-564D-4B35-8C92-C947F5216862",
    "form_completion_date": "2012-4-30",
    "pharmaceutical_therapy_drug_name": "AFLIBERCEPT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 471,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "F788F950-7953-47A6-B833-F9E5DAA28FD3",
    "patient_ID": "TCGA.ER.A2NG",
    "bcr_drug_barcode": "TCGA-ER-A2NG-D31364",
    "bcr_drug_uuid": "153DB23C-8C39-422B-B68D-CB1FCC1BFFDA",
    "form_completion_date": "2012-5-1",
    "pharmaceutical_therapy_drug_name": "IL-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 705,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 766,
    "drug_cycles": 2,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "F788F950-7953-47A6-B833-F9E5DAA28FD3",
    "patient_ID": "TCGA.ER.A2NG",
    "bcr_drug_barcode": "TCGA-ER-A2NG-D31365",
    "bcr_drug_uuid": "AC54798F-04E6-49C4-9191-07BC7B0E9D91",
    "form_completion_date": "2012-5-1",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 889,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_dose": 480,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "F788F950-7953-47A6-B833-F9E5DAA28FD3",
    "patient_ID": "TCGA.ER.A2NG",
    "bcr_drug_barcode": "TCGA-ER-A2NG-D31362",
    "bcr_drug_uuid": "9D7C3E9C-BA8F-478D-8A27-BA1D14E0BD75",
    "form_completion_date": "2012-5-1",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 578,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 609,
    "drug_cycles": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "E35BE832-6972-4677-B985-02E90D51141A",
    "patient_ID": "TCGA.ER.A3EV",
    "bcr_drug_barcode": "TCGA-ER-A3EV-D63404",
    "bcr_drug_uuid": "A322103D-E689-49A3-AFF9-C11F3090F90C",
    "form_completion_date": "2014-8-7",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 366,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 366,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "F1A69042-8347-45C1-B925-8526A8443B86",
    "patient_ID": "TCGA.FR.A2OS",
    "bcr_drug_barcode": "TCGA-FR-A2OS-D31068",
    "bcr_drug_uuid": "DBF55362-6EE0-4BFB-8392-B1C1D3AE910C",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "TEMODAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 311,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 368,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 400,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "F027DA44-6ADC-4207-93AC-E8BF45A1BF3D",
    "patient_ID": "TCGA.FR.A3YN",
    "bcr_drug_barcode": "TCGA-FR-A3YN-D35304",
    "bcr_drug_uuid": "6F4B77B1-79A0-404F-AA23-1DA625843E16",
    "form_completion_date": "2012-9-24",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2324,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2387,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "62E928C1-DF8B-4771-AE46-5DA40794DAF2",
    "patient_ID": "TCGA.FR.A3YO",
    "bcr_drug_barcode": "TCGA-FR-A3YO-D35306",
    "bcr_drug_uuid": "EB7F62DE-63D0-46E6-918C-91D76FA67219",
    "form_completion_date": "2012-9-24",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "18E7B73C-4520-42CD-AC9B-23BAC1C8ECC6",
    "patient_ID": "TCGA.FR.A44A",
    "bcr_drug_barcode": "TCGA-FR-A44A-D36533",
    "bcr_drug_uuid": "B4B54E08-6033-4A25-9C4A-3E12F48604B6",
    "form_completion_date": "2012-11-1",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2769,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3134,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CCF8809A-CDFD-46F7-B607-001B8B91C1A4",
    "patient_ID": "TCGA.FR.A69P",
    "bcr_drug_barcode": "TCGA-FR-A69P-D44395",
    "bcr_drug_uuid": "91FA2BDB-09FC-4E3E-882F-A60144B4870C",
    "form_completion_date": "2013-8-14",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 107,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "EA6337B3-3B5E-489E-AE2F-2908447F6300",
    "patient_ID": "TCGA.FR.A728",
    "bcr_drug_barcode": "TCGA-FR-A728-D55557",
    "bcr_drug_uuid": "B6DA4C3C-D6DA-44D6-8E7D-402461E003EA",
    "form_completion_date": "2014-1-8",
    "pharmaceutical_therapy_drug_name": "DABRAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 100,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 119,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "EA6337B3-3B5E-489E-AE2F-2908447F6300",
    "patient_ID": "TCGA.FR.A728",
    "bcr_drug_barcode": "TCGA-FR-A728-D55558",
    "bcr_drug_uuid": "CABC63ED-6661-4C29-8EA2-FA5511964A9B",
    "form_completion_date": "2014-1-8",
    "pharmaceutical_therapy_drug_name": "TRAMETINIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 100,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 119,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "F55914F3-F19A-4D93-B368-554EC1A9CF40",
    "patient_ID": "TCGA.FR.A729",
    "bcr_drug_barcode": "TCGA-FR-A729-D55580",
    "bcr_drug_uuid": "EE24C048-2D8C-4DC9-8BF4-C2C6A55E5B55",
    "form_completion_date": "2014-1-9",
    "pharmaceutical_therapy_drug_name": "SYLATRON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 6253,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23809CE7-77B4-432F-BDA2-678F822B604A",
    "patient_ID": "TCGA.FR.A7U8",
    "bcr_drug_barcode": "TCGA-FR-A7U8-D54414",
    "bcr_drug_uuid": "4D760785-4509-4E2E-8278-99B4C938A789",
    "form_completion_date": "2013-12-18",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 89,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 208,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "1FB5B4FD-8891-4A21-96B6-45D4B848CC66",
    "patient_ID": "TCGA.FR.A7U9",
    "bcr_drug_barcode": "TCGA-FR-A7U9-D54429",
    "bcr_drug_uuid": "B35ABA94-FE7A-4259-B496-F2363B35A93A",
    "form_completion_date": "2013-12-18",
    "pharmaceutical_therapy_drug_name": "TALIMOGENE LAHERPAREPVEC (T-VEC)",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 115,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 178,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "1FB5B4FD-8891-4A21-96B6-45D4B848CC66",
    "patient_ID": "TCGA.FR.A7U9",
    "bcr_drug_barcode": "TCGA-FR-A7U9-D54434",
    "bcr_drug_uuid": "CAE956A0-4CBF-4CEC-AD76-EF82687633AD",
    "form_completion_date": "2013-12-18",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "D781260C-F969-456E-BF16-044DC5B181A4",
    "patient_ID": "TCGA.FR.A8YC",
    "bcr_drug_barcode": "TCGA-FR-A8YC-D57417",
    "bcr_drug_uuid": "6A4EF828-9108-4D8F-ACAD-30422C32DF04",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "2B3-101",
    "clinical_trial_drug_classification": "LIPOSOMAL DOXORUBICIN CONJUGATED TO GLUTATHIONE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1020,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1020,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2897A728-EC7B-4321-B0FE-3575B7C6EE39",
    "patient_ID": "TCGA.FR.A8YD",
    "bcr_drug_barcode": "TCGA-FR-A8YD-D57428",
    "bcr_drug_uuid": "8F6DA52E-4C2C-47EF-866A-50272C234141",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 812,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 880,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2C79ADD1-8093-4E81-8F80-069AF7B7C2FA",
    "patient_ID": "TCGA.FS.A1ZE",
    "bcr_drug_barcode": "TCGA-FS-A1ZE-D62035",
    "bcr_drug_uuid": "7762BB1A-E8F6-4DF3-B9CC-B92F213CD077",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "DTIC",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 651,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 761,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2C79ADD1-8093-4E81-8F80-069AF7B7C2FA",
    "patient_ID": "TCGA.FS.A1ZE",
    "bcr_drug_barcode": "TCGA-FS-A1ZE-D62036",
    "bcr_drug_uuid": "9E87E85D-D028-49BD-A25A-570A54909894",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "PACLITAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 762,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 853,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2C79ADD1-8093-4E81-8F80-069AF7B7C2FA",
    "patient_ID": "TCGA.FS.A1ZE",
    "bcr_drug_barcode": "TCGA-FS-A1ZE-D62037",
    "bcr_drug_uuid": "2D51DC19-E8CC-4DF1-930C-698AA19EAE3C",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "ANGIOCAL",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 896,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1034,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2C79ADD1-8093-4E81-8F80-069AF7B7C2FA",
    "patient_ID": "TCGA.FS.A1ZE",
    "bcr_drug_barcode": "TCGA-FS-A1ZE-D62039",
    "bcr_drug_uuid": "EA4287BB-3EC7-4070-B547-CCA6E591A5CB",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN_PACLITAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1188,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1249,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2C79ADD1-8093-4E81-8F80-069AF7B7C2FA",
    "patient_ID": "TCGA.FS.A1ZE",
    "bcr_drug_barcode": "TCGA-FS-A1ZE-D66925",
    "bcr_drug_uuid": "5E7D38CF-5687-4848-AFAB-C3DBA39E24E2",
    "form_completion_date": "2014-10-28",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN PACLITAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1188,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1249,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "31E94518-F6DD-4458-94D8-DDA3CC7A0831",
    "patient_ID": "TCGA.FS.A1ZS",
    "bcr_drug_barcode": "TCGA-FS-A1ZS-D62240",
    "bcr_drug_uuid": "1DA58199-D6CD-4CF8-ADAF-59F04EB78068",
    "form_completion_date": "2014-7-15",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2566,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2790,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "57882F61-4A32-49F1-AFD4-61C70B184D8B",
    "patient_ID": "TCGA.FS.A1ZT",
    "bcr_drug_barcode": "TCGA-FS-A1ZT-D62242",
    "bcr_drug_uuid": "7BE14272-B795-4782-BA4E-938A64A8227C",
    "form_completion_date": "2014-7-15",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 398,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1053,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "49A6F6A6-BF6F-45CF-93DC-B006B4A0637D",
    "patient_ID": "TCGA.FS.A1ZW",
    "bcr_drug_barcode": "TCGA-FS-A1ZW-D62253",
    "bcr_drug_uuid": "125D0F7B-4176-4DD7-B911-D366B3DD599F",
    "form_completion_date": "2014-7-15",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 700,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1005,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4EB16FB1-0FCF-4C47-80FA-B7ACC3A59A12",
    "patient_ID": "TCGA.FS.A4F0",
    "bcr_drug_barcode": "TCGA-FS-A4F0-D62026",
    "bcr_drug_uuid": "0D667BAE-1A9F-4131-ADCA-09371B34D1BE",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "TREOSULFAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1543,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1603,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "4EB16FB1-0FCF-4C47-80FA-B7ACC3A59A12",
    "patient_ID": "TCGA.FS.A4F0",
    "bcr_drug_barcode": "TCGA-FS-A4F0-D62030",
    "bcr_drug_uuid": "AF5AB1F3-9D07-4C97-A272-6BE687C1D370",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 82,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 568,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4EB16FB1-0FCF-4C47-80FA-B7ACC3A59A12",
    "patient_ID": "TCGA.FS.A4F0",
    "bcr_drug_barcode": "TCGA-FS-A4F0-D62031",
    "bcr_drug_uuid": "2D32AFB5-F3B4-41E8-A29D-6BD93EB2EB77",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "DTIC",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1359,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1521,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4EB16FB1-0FCF-4C47-80FA-B7ACC3A59A12",
    "patient_ID": "TCGA.FS.A4F0",
    "bcr_drug_barcode": "TCGA-FS-A4F0-D70506",
    "bcr_drug_uuid": "7E48CFDF-D865-4A66-BD8F-13981DA5AD94",
    "form_completion_date": "2015-2-25",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1543,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1603,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0CAA706A-251F-43A0-897A-111AEC0ACC82",
    "patient_ID": "TCGA.FS.A4F9",
    "bcr_drug_barcode": "TCGA-FS-A4F9-D62028",
    "bcr_drug_uuid": "1AAC216C-136D-4B9A-BADF-2872BE40FBAD",
    "form_completion_date": "2014-7-11",
    "pharmaceutical_therapy_drug_name": "TEMODAL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1035,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E5BC45CE-8A14-40B5-B9B5-CE45609FEF3A",
    "patient_ID": "TCGA.FW.A3R5",
    "bcr_drug_barcode": "TCGA-FW-A3R5-D42774",
    "bcr_drug_uuid": "E3483732-A7D0-4D36-A161-AADFE003D9A4",
    "form_completion_date": "2013-4-30",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 714,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 993,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "04C3D01D-A949-4DC7-9829-A8C99180DBA0",
    "patient_ID": "TCGA.FW.A3TV",
    "bcr_drug_barcode": "TCGA-FW-A3TV-D58959",
    "bcr_drug_uuid": "E0B26F0B-5AE2-42A2-8D55-8C54C43405E9",
    "form_completion_date": "2014-4-29",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 33,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 58,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "04C3D01D-A949-4DC7-9829-A8C99180DBA0",
    "patient_ID": "TCGA.FW.A3TV",
    "bcr_drug_barcode": "TCGA-FW-A3TV-D58960",
    "bcr_drug_uuid": "45A797FA-4FC2-4894-AC34-971D4814A6F4",
    "form_completion_date": "2014-4-29",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F94AE8F2-D555-4C2A-97B0-DBE7D642C566",
    "patient_ID": "TCGA.GF.A3OT",
    "bcr_drug_barcode": "TCGA-GF-A3OT-D33548",
    "bcr_drug_uuid": "1186E0F3-0CCF-442F-B0D1-5A21422B21E8",
    "form_completion_date": "2012-7-5",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 95,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F94AE8F2-D555-4C2A-97B0-DBE7D642C566",
    "patient_ID": "TCGA.GF.A3OT",
    "bcr_drug_barcode": "TCGA-GF-A3OT-D33549",
    "bcr_drug_uuid": "D6878F25-0FA5-4C49-BBD7-E8CB3CCBD96F",
    "form_completion_date": "2012-7-5",
    "pharmaceutical_therapy_drug_name": "TAXOL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 95,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F94AE8F2-D555-4C2A-97B0-DBE7D642C566",
    "patient_ID": "TCGA.GF.A3OT",
    "bcr_drug_barcode": "TCGA-GF-A3OT-D33550",
    "bcr_drug_uuid": "52AF2AFE-648C-4C38-9D6A-A4F98F4AE74F",
    "form_completion_date": "2012-7-5",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 95,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F94AE8F2-D555-4C2A-97B0-DBE7D642C566",
    "patient_ID": "TCGA.GF.A3OT",
    "bcr_drug_barcode": "TCGA-GF-A3OT-D33551",
    "bcr_drug_uuid": "48514E36-5918-4104-AC4E-5D0B107FD361",
    "form_completion_date": "2012-7-5",
    "pharmaceutical_therapy_drug_name": "YERVOY",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 249,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 249,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "76CC1D42-ACEC-46B3-9663-5E4DE2550353",
    "patient_ID": "TCGA.GN.A264",
    "bcr_drug_barcode": "TCGA-GN-A264-D30984",
    "bcr_drug_uuid": "C4BF706E-13DD-4EED-9930-25B1A48DEAC4",
    "form_completion_date": "2012-4-12",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALFA-2B",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2752,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3111,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "AB74D6ED-880E-4470-BFD5-2974A4C3A0D7",
    "patient_ID": "TCGA.GN.A267",
    "bcr_drug_barcode": "TCGA-GN-A267-D30978",
    "bcr_drug_uuid": "49886711-7400-471F-97A7-3B5A0208A487",
    "form_completion_date": "2012-4-12",
    "pharmaceutical_therapy_drug_name": "TEMODAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1520,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1530,
    "regimen_number": 1,
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "B6B51B28-BDEE-4FE6-A3F3-7B128E16721C",
    "patient_ID": "TCGA.GN.A26D",
    "bcr_drug_barcode": "TCGA-GN-A26D-D31124",
    "bcr_drug_uuid": "336D254D-7027-4C59-8825-F1B6ECCDF279",
    "form_completion_date": "2012-4-12",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 757,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 757,
    "pharma_type_other": "ISOLATED LIMB PERFUSION (ILP)",
    "regimen_number": 1,
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "AT SAME TIME AS SURGERY"
  },
  {
    "bcr_patient_uuid": "909335D0-BB4B-4EA3-869A-93E4D91C2154",
    "patient_ID": "TCGA.GN.A4U3",
    "bcr_drug_barcode": "TCGA-GN-A4U3-D46831",
    "bcr_drug_uuid": "EAB33659-E9EC-4299-A9BB-9CE2D8EE0B1C",
    "form_completion_date": "2013-8-19",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2299,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2574,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6DC9C5B0-77E6-4C53-A75C-8F01731C54E8",
    "patient_ID": "TCGA.GN.A4U4",
    "bcr_drug_barcode": "TCGA-GN-A4U4-D46802",
    "bcr_drug_uuid": "48687698-3009-4D4E-8693-339068E62E60",
    "form_completion_date": "2013-8-19",
    "pharmaceutical_therapy_drug_name": "AXITINIB",
    "clinical_trial_drug_classification": "AXITNIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 245,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 647,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "6DC9C5B0-77E6-4C53-A75C-8F01731C54E8",
    "patient_ID": "TCGA.GN.A4U4",
    "bcr_drug_barcode": "TCGA-GN-A4U4-D46803",
    "bcr_drug_uuid": "AB166A1C-9C3F-4D46-B14A-CABAA55EDF0B",
    "form_completion_date": "2013-8-19",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 637,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 707,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C35D97F8-1B70-4FBD-A603-9230B3BA7952",
    "patient_ID": "TCGA.GN.A4U5",
    "bcr_drug_barcode": "TCGA-GN-A4U5-D46800",
    "bcr_drug_uuid": "D437D4B7-BEBA-4E21-B266-29C50FD7238C",
    "form_completion_date": "2013-8-19",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 211,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 435,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "088C296E-8E13-4DC8-8A99-B27F4B27F95E",
    "patient_ID": "TCGA.GN.A4U7",
    "bcr_drug_barcode": "TCGA-GN-A4U7-D46807",
    "bcr_drug_uuid": "91BCC069-9392-4F6C-B6E8-B794A2A8D9B5",
    "form_completion_date": "2013-8-19",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 190,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D3B77DA8-BE1D-4955-B1C7-55B7769785E8",
    "patient_ID": "TCGA.GN.A4U8",
    "bcr_drug_barcode": "TCGA-GN-A4U8-D67434",
    "bcr_drug_uuid": "9A1377ED-6CA2-400A-9E60-60837D62CCBE",
    "form_completion_date": "2014-11-5",
    "pharmaceutical_therapy_drug_name": "SYLATRON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1186,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AB7EB3EC-BD87-4E49-9010-B51B17148F7C",
    "patient_ID": "TCGA.GN.A4U9",
    "bcr_drug_barcode": "TCGA-GN-A4U9-D46811",
    "bcr_drug_uuid": "104BF2C9-701E-4587-AF21-E91ED4AC09E4",
    "form_completion_date": "2013-8-19",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 165,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 249,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AB7EB3EC-BD87-4E49-9010-B51B17148F7C",
    "patient_ID": "TCGA.GN.A4U9",
    "bcr_drug_barcode": "TCGA-GN-A4U9-D61278",
    "bcr_drug_uuid": "ABA25B40-E4EC-4E58-8CF7-84B6989E8EE6",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "MELPHALAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 60,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AB7EB3EC-BD87-4E49-9010-B51B17148F7C",
    "patient_ID": "TCGA.GN.A4U9",
    "bcr_drug_barcode": "TCGA-GN-A4U9-D61279",
    "bcr_drug_uuid": "DE681125-464A-47F1-98C1-1FB4B8EAAD4A",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "IMIQUIMOD",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 384,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AB7EB3EC-BD87-4E49-9010-B51B17148F7C",
    "patient_ID": "TCGA.GN.A4U9",
    "bcr_drug_barcode": "TCGA-GN-A4U9-D61281",
    "bcr_drug_uuid": "026B90A1-398A-49A0-9EBE-CE0B7F3BE347",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "AXITINIB",
    "clinical_trial_drug_classification": "CHEMOTHERAPY",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 523,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 579,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "962FF090-16C0-438B-8213-86B2BD306E4C",
    "patient_ID": "TCGA.GN.A8LK",
    "bcr_drug_barcode": "TCGA-GN-A8LK-D58257",
    "bcr_drug_uuid": "61C2C4C7-384F-4ACD-99CB-9B4287758D0D",
    "form_completion_date": "2014-4-3",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1248,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1269,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "962FF090-16C0-438B-8213-86B2BD306E4C",
    "patient_ID": "TCGA.GN.A8LK",
    "bcr_drug_barcode": "TCGA-GN-A8LK-D58248",
    "bcr_drug_uuid": "A0C95321-3246-438C-BC36-81C43E81DC6A",
    "form_completion_date": "2014-4-3",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1493,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1513,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "962FF090-16C0-438B-8213-86B2BD306E4C",
    "patient_ID": "TCGA.GN.A8LK",
    "bcr_drug_barcode": "TCGA-GN-A8LK-D58249",
    "bcr_drug_uuid": "6F02B9B4-2E3C-407B-B449-0BAADD6BC667",
    "form_completion_date": "2014-4-3",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1407,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1428,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "7F7BC51F-7F75-4796-9CE5-A4735C3C0807",
    "patient_ID": "TCGA.GN.A8LN",
    "bcr_drug_barcode": "TCGA-GN-A8LN-D67402",
    "bcr_drug_uuid": "BCE3BE49-6608-4A70-9687-0ACFA271E31A",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 464,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 464,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7F7BC51F-7F75-4796-9CE5-A4735C3C0807",
    "patient_ID": "TCGA.GN.A8LN",
    "bcr_drug_barcode": "TCGA-GN-A8LN-D67403",
    "bcr_drug_uuid": "168A547C-A5E1-4C75-9792-8D2E422EABE3",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "days_to_drug_start": 603,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7F7BC51F-7F75-4796-9CE5-A4735C3C0807",
    "patient_ID": "TCGA.GN.A8LN",
    "bcr_drug_barcode": "TCGA-GN-A8LN-D67404",
    "bcr_drug_uuid": "2DD12825-B254-43A9-BB1E-D85F68B59CBC",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "PACLITAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 603,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7F7BC51F-7F75-4796-9CE5-A4735C3C0807",
    "patient_ID": "TCGA.GN.A8LN",
    "bcr_drug_barcode": "TCGA-GN-A8LN-D72289",
    "bcr_drug_uuid": "CCBCEAEE-76F5-469C-9D35-BE5F7C39C534",
    "form_completion_date": "2015-5-4",
    "pharmaceutical_therapy_drug_name": "PEMBROLIZUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 772,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EC4C4296-6AB4-420C-80A4-E7A34B9BF4A2",
    "patient_ID": "TCGA.GN.A9SD",
    "bcr_drug_barcode": "TCGA-GN-A9SD-D61261",
    "bcr_drug_uuid": "F65A7C23-E8EE-4C17-83E2-FE0459FC7B01",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "ACTINOMYCIN D",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1268,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1268,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EC4C4296-6AB4-420C-80A4-E7A34B9BF4A2",
    "patient_ID": "TCGA.GN.A9SD",
    "bcr_drug_barcode": "TCGA-GN-A9SD-D61262",
    "bcr_drug_uuid": "CED20E6D-56DA-4652-A6E8-441AC129A7F2",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "MELPHALAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1366,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1366,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EC4C4296-6AB4-420C-80A4-E7A34B9BF4A2",
    "patient_ID": "TCGA.GN.A9SD",
    "bcr_drug_barcode": "TCGA-GN-A9SD-D61264",
    "bcr_drug_uuid": "CCF59FEE-AB6E-4C88-A9D5-A1FF349E15F8",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1519,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1687,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EC4C4296-6AB4-420C-80A4-E7A34B9BF4A2",
    "patient_ID": "TCGA.GN.A9SD",
    "bcr_drug_barcode": "TCGA-GN-A9SD-D61267",
    "bcr_drug_uuid": "9297715F-2400-4139-AF60-263A265A2C54",
    "form_completion_date": "2014-6-26",
    "pharmaceutical_therapy_drug_name": "MELPHALAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1268,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1268,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6668ACFE-1594-42C0-B839-8A592702675F",
    "patient_ID": "TCGA.HR.A2OH",
    "bcr_drug_barcode": "TCGA-HR-A2OH-D35734",
    "bcr_drug_uuid": "14B225B5-367B-4D68-B6E0-921D5DCF5561",
    "form_completion_date": "2012-10-16",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 108,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 471,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6668ACFE-1594-42C0-B839-8A592702675F",
    "patient_ID": "TCGA.HR.A2OH",
    "bcr_drug_barcode": "TCGA-HR-A2OH-D35737",
    "bcr_drug_uuid": "E4A61CA2-56B3-4AC8-BE92-8D8329B14C09",
    "form_completion_date": "2012-10-16",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1729,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1753,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6668ACFE-1594-42C0-B839-8A592702675F",
    "patient_ID": "TCGA.HR.A2OH",
    "bcr_drug_barcode": "TCGA-HR-A2OH-D35741",
    "bcr_drug_uuid": "2D3DBDD6-6191-489A-B366-69852B8AA8B3",
    "form_completion_date": "2012-10-16",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN - 2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1830,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1848,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2BDB65A5-4B72-4379-822D-69CC41FD663F",
    "patient_ID": "TCGA.QB.AA9O",
    "bcr_drug_barcode": "TCGA-QB-AA9O-D60729",
    "bcr_drug_uuid": "CD3E7E8E-E439-4BEC-9C20-21CFAF1A9EE5",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 171,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 234,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ED471051-41DC-404C-87EC-DB4A281ECFB5",
    "patient_ID": "TCGA.W3.A824",
    "bcr_drug_barcode": "TCGA-W3-A824-D57952",
    "bcr_drug_uuid": "3D9848B9-95F4-4B8E-9B12-0E16E0A5B3C5",
    "form_completion_date": "2014-3-31",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1491,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2710,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2F5D8110-35C7-419F-8B35-BC3040F940F3",
    "patient_ID": "TCGA.W3.A825",
    "bcr_drug_barcode": "TCGA-W3-A825-D57947",
    "bcr_drug_uuid": "3493FCF2-8598-4291-972C-E0184ECA691A",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1644,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1767,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F5D8110-35C7-419F-8B35-BC3040F940F3",
    "patient_ID": "TCGA.W3.A825",
    "bcr_drug_barcode": "TCGA-W3-A825-D59255",
    "bcr_drug_uuid": "B8BEA87F-2415-4525-A51B-1A3E320FBFED",
    "form_completion_date": "2014-5-6",
    "pharmaceutical_therapy_drug_name": "VINBLASTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1644,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1767,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F5D8110-35C7-419F-8B35-BC3040F940F3",
    "patient_ID": "TCGA.W3.A825",
    "bcr_drug_barcode": "TCGA-W3-A825-D59256",
    "bcr_drug_uuid": "E2963A06-F227-4313-8A57-804FCDFB892A",
    "form_completion_date": "2014-5-6",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1644,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1767,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F5D8110-35C7-419F-8B35-BC3040F940F3",
    "patient_ID": "TCGA.W3.A825",
    "bcr_drug_barcode": "TCGA-W3-A825-D59257",
    "bcr_drug_uuid": "629BC50C-21B1-4874-B541-81D0A4F1AAB6",
    "form_completion_date": "2014-5-6",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1644,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1767,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F5D8110-35C7-419F-8B35-BC3040F940F3",
    "patient_ID": "TCGA.W3.A825",
    "bcr_drug_barcode": "TCGA-W3-A825-D59258",
    "bcr_drug_uuid": "7821BEA2-841B-4A03-AA6D-4518D9F20C47",
    "form_completion_date": "2014-5-6",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1644,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1767,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2F5D8110-35C7-419F-8B35-BC3040F940F3",
    "patient_ID": "TCGA.W3.A825",
    "bcr_drug_barcode": "TCGA-W3-A825-D59259",
    "bcr_drug_uuid": "A0F6E18A-B10B-4902-89AA-BF9808530488",
    "form_completion_date": "2014-5-6",
    "pharmaceutical_therapy_drug_name": "INTERFERON-?2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1644,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1767,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BA207D79-91C0-45DC-A784-4BCAEC580EB4",
    "patient_ID": "TCGA.W3.A828",
    "bcr_drug_barcode": "TCGA-W3-A828-D57943",
    "bcr_drug_uuid": "E6458654-BF4E-4083-B115-2455F34B79B6",
    "form_completion_date": "2014-3-31",
    "clinical_trial_drug_classification": "GMCSF",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1887,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2283,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "DB950F20-C869-4E1A-ADA2-DBDC82B5865E",
    "patient_ID": "TCGA.W3.AA1O",
    "bcr_drug_barcode": "TCGA-W3-AA1O-D61896",
    "bcr_drug_uuid": "D5AA006A-D5B5-427A-84DF-EAF25033C4BD",
    "form_completion_date": "2014-7-9",
    "pharmaceutical_therapy_drug_name": "CARMUSTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DB950F20-C869-4E1A-ADA2-DBDC82B5865E",
    "patient_ID": "TCGA.W3.AA1O",
    "bcr_drug_barcode": "TCGA-W3-AA1O-D61897",
    "bcr_drug_uuid": "ED899617-E068-4510-BBA9-961A458E5461",
    "form_completion_date": "2014-7-9",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DB950F20-C869-4E1A-ADA2-DBDC82B5865E",
    "patient_ID": "TCGA.W3.AA1O",
    "bcr_drug_barcode": "TCGA-W3-AA1O-D61898",
    "bcr_drug_uuid": "AF74B106-14D2-4701-97C2-F83ABE6480E7",
    "form_completion_date": "2014-7-9",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DB950F20-C869-4E1A-ADA2-DBDC82B5865E",
    "patient_ID": "TCGA.W3.AA1O",
    "bcr_drug_barcode": "TCGA-W3-AA1O-D61899",
    "bcr_drug_uuid": "C2D8F52F-1FE8-4192-A751-446D06312B6D",
    "form_completion_date": "2014-7-9",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "81807B84-DA9C-4847-A303-5A8C7297127C",
    "patient_ID": "TCGA.W3.AA1Q",
    "bcr_drug_barcode": "TCGA-W3-AA1Q-D62013",
    "bcr_drug_uuid": "A7A2B5D3-CD67-4ACB-B405-9F403544CE8A",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 1735,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "81807B84-DA9C-4847-A303-5A8C7297127C",
    "patient_ID": "TCGA.W3.AA1Q",
    "bcr_drug_barcode": "TCGA-W3-AA1Q-D62011",
    "bcr_drug_uuid": "0AB73F01-3AA9-423C-AA65-5ED7AD1866D8",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "HERCEPTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1735,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "81807B84-DA9C-4847-A303-5A8C7297127C",
    "patient_ID": "TCGA.W3.AA1Q",
    "bcr_drug_barcode": "TCGA-W3-AA1Q-D62003",
    "bcr_drug_uuid": "87B9AEA1-BB2A-4A7E-B450-19716583263C",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1492,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "81807B84-DA9C-4847-A303-5A8C7297127C",
    "patient_ID": "TCGA.W3.AA1Q",
    "bcr_drug_barcode": "TCGA-W3-AA1Q-D62012",
    "bcr_drug_uuid": "5A4729CA-D269-40EB-B347-EE660C746E21",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "DENDRITIC CELL THERAPY",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1735,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "81807B84-DA9C-4847-A303-5A8C7297127C",
    "patient_ID": "TCGA.W3.AA1Q",
    "bcr_drug_barcode": "TCGA-W3-AA1Q-D62010",
    "bcr_drug_uuid": "47A8FABB-17DD-4089-AA7B-C16923DA985A",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1735,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "81807B84-DA9C-4847-A303-5A8C7297127C",
    "patient_ID": "TCGA.W3.AA1Q",
    "bcr_drug_barcode": "TCGA-W3-AA1Q-D61974",
    "bcr_drug_uuid": "1847D54C-5C9F-426C-9678-31CED121E3B8",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 913,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "53FBE99C-180C-45E6-8585-796028B3D118",
    "patient_ID": "TCGA.W3.AA1R",
    "bcr_drug_barcode": "TCGA-W3-AA1R-D62139",
    "bcr_drug_uuid": "2DB7E4AF-9DAE-4798-A1AF-0E4B18DF2C25",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "TCV",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 792,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2192,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "53FBE99C-180C-45E6-8585-796028B3D118",
    "patient_ID": "TCGA.W3.AA1R",
    "bcr_drug_barcode": "TCGA-W3-AA1R-D62156",
    "bcr_drug_uuid": "EC06585D-C5A8-4BBB-A46F-465270BAF31D",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "VACCINE",
    "days_to_drug_start": 1006,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2863,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "53FBE99C-180C-45E6-8585-796028B3D118",
    "patient_ID": "TCGA.W3.AA1R",
    "bcr_drug_barcode": "TCGA-W3-AA1R-D62160",
    "bcr_drug_uuid": "0790043A-09BB-455E-8CDA-62093F904149",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "CANVAX",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2526,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3349,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "53FBE99C-180C-45E6-8585-796028B3D118",
    "patient_ID": "TCGA.W3.AA1R",
    "bcr_drug_barcode": "TCGA-W3-AA1R-D62158",
    "bcr_drug_uuid": "10E6C144-9977-4102-93B4-322E910F9964",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "IL2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 3105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "9817EC15-605A-40DB-B848-2199E5CCBB7B",
    "patient_ID": "TCGA.W3.AA1V",
    "bcr_drug_barcode": "TCGA-W3-AA1V-D62292",
    "bcr_drug_uuid": "E9378015-7AB8-4F9F-B6BE-8E66FE21B2B7",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1005,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1280,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "36F4BE75-CBCF-431B-9199-DBA295A905A1",
    "patient_ID": "TCGA.W3.AA1W",
    "bcr_drug_barcode": "TCGA-W3-AA1W-D62342",
    "bcr_drug_uuid": "5C9B4049-50B4-42FC-B5E4-E3840532F7E0",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 335,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 761,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "36F4BE75-CBCF-431B-9199-DBA295A905A1",
    "patient_ID": "TCGA.W3.AA1W",
    "bcr_drug_barcode": "TCGA-W3-AA1W-D62343",
    "bcr_drug_uuid": "2A0864D3-1A42-4B06-A486-5DAD8629672C",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "VACCINE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1065,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1765,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "4A9E5DC0-6FC3-47E0-8470-DAC16CE16DA3",
    "patient_ID": "TCGA.W3.AA21",
    "bcr_drug_barcode": "TCGA-W3-AA21-D62454",
    "bcr_drug_uuid": "87E7F2A0-DFEE-43A5-A83B-9AAC109954F7",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "TAXOL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3075,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4A9E5DC0-6FC3-47E0-8470-DAC16CE16DA3",
    "patient_ID": "TCGA.W3.AA21",
    "bcr_drug_barcode": "TCGA-W3-AA21-D62455",
    "bcr_drug_uuid": "3171F663-933C-4459-AB16-F6F3DC6A1C7B",
    "form_completion_date": "2014-7-17",
    "pharmaceutical_therapy_drug_name": "TEMODAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3075,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4A9E5DC0-6FC3-47E0-8470-DAC16CE16DA3",
    "patient_ID": "TCGA.W3.AA21",
    "bcr_drug_barcode": "TCGA-W3-AA21-D62452",
    "bcr_drug_uuid": "6DD268A6-11C7-42FA-93A6-D78BB7888554",
    "form_completion_date": "2014-7-17",
    "clinical_trial_drug_classification": "TCV",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1065,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2100,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0F579238-5A11-4ADC-9C80-572CBB2CE58F",
    "patient_ID": "TCGA.WE.A8K5",
    "bcr_drug_barcode": "TCGA-WE-A8K5-D67279",
    "bcr_drug_uuid": "4F22B8A1-36C5-44EA-AEB9-3738C17AE1C4",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1823,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1860,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8D7F8F4D-AEF9-4D1B-BFB4-7ED85B0797B3",
    "patient_ID": "TCGA.WE.A8K6",
    "bcr_drug_barcode": "TCGA-WE-A8K6-D67322",
    "bcr_drug_uuid": "D3A92AC3-641B-4CB5-9659-6449894618B0",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 294,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F8E01148-6FC7-4451-B24A-F3510CD24F9D",
    "patient_ID": "TCGA.WE.A8ZM",
    "bcr_drug_barcode": "TCGA-WE-A8ZM-D67242",
    "bcr_drug_uuid": "713037E7-955D-4BF5-9F23-5F14720D99D7",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "DIPHENCYPRONE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 2946,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F311877D-021A-423B-A6F5-E574C9A3CA7C",
    "patient_ID": "TCGA.WE.A8ZN",
    "bcr_drug_barcode": "TCGA-WE-A8ZN-D64452",
    "bcr_drug_uuid": "3991EC25-0547-4967-9567-7EF9A6338B9D",
    "form_completion_date": "2014-9-8",
    "pharmaceutical_therapy_drug_name": "NIVOLUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1533,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1618,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "77052F40-374E-4DAE-BC17-908B52DB0F08",
    "patient_ID": "TCGA.WE.A8ZQ",
    "bcr_drug_barcode": "TCGA-WE-A8ZQ-D67271",
    "bcr_drug_uuid": "81D57578-ACE2-4F1D-A680-009CD4884B3E",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1818,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "77052F40-374E-4DAE-BC17-908B52DB0F08",
    "patient_ID": "TCGA.WE.A8ZQ",
    "bcr_drug_barcode": "TCGA-WE-A8ZQ-D70248",
    "bcr_drug_uuid": "DB97B379-0939-4194-8DCA-C2C51F714578",
    "form_completion_date": "2015-2-11",
    "pharmaceutical_therapy_drug_name": "DABRAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1853,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "56D4CA9B-C050-45B4-B636-03FE2251FA1A",
    "patient_ID": "TCGA.WE.A8ZR",
    "bcr_drug_barcode": "TCGA-WE-A8ZR-D67324",
    "bcr_drug_uuid": "B445763E-9415-4BEA-9CA8-7DD8DD3BEDE0",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 137,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 261,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ADFA6BEB-1AA3-4A2A-AFE7-8D036A80B20D",
    "patient_ID": "TCGA.WE.AAA0",
    "bcr_drug_barcode": "TCGA-WE-AAA0-D67375",
    "bcr_drug_uuid": "ABFA30DE-189E-4F48-9E24-6B8B25ACF046",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 856,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 917,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ADFA6BEB-1AA3-4A2A-AFE7-8D036A80B20D",
    "patient_ID": "TCGA.WE.AAA0",
    "bcr_drug_barcode": "TCGA-WE-AAA0-D70282",
    "bcr_drug_uuid": "43DE3CA7-A2A2-45E4-879F-D4ED0B184FE0",
    "form_completion_date": "2015-2-9",
    "pharmaceutical_therapy_drug_name": "PEMBROLIZUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1166,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "99706AD3-5CF4-45F8-815E-51E78F2E9F79",
    "patient_ID": "TCGA.WE.AAA4",
    "bcr_drug_barcode": "TCGA-WE-AAA4-D63852",
    "bcr_drug_uuid": "8E1A8681-1E06-43ED-9331-24D2371A9E83",
    "form_completion_date": "2014-9-22",
    "pharmaceutical_therapy_drug_name": "MELPHALAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 360,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 360,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "99706AD3-5CF4-45F8-815E-51E78F2E9F79",
    "patient_ID": "TCGA.WE.AAA4",
    "bcr_drug_barcode": "TCGA-WE-AAA4-D67390",
    "bcr_drug_uuid": "80599AC8-6F29-42D4-B2C5-42B5FF3DB16A",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "VEMURAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 517,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 527,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "99706AD3-5CF4-45F8-815E-51E78F2E9F79",
    "patient_ID": "TCGA.WE.AAA4",
    "bcr_drug_barcode": "TCGA-WE-AAA4-D67392",
    "bcr_drug_uuid": "A5F48421-10FD-4DA2-9EF9-58EC39006C3B",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "DABRAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 535,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "99706AD3-5CF4-45F8-815E-51E78F2E9F79",
    "patient_ID": "TCGA.WE.AAA4",
    "bcr_drug_barcode": "TCGA-WE-AAA4-D70348",
    "bcr_drug_uuid": "EB201F0B-CCB8-4926-B098-B0586C8F0FF0",
    "form_completion_date": "2015-2-9",
    "pharmaceutical_therapy_drug_name": "IPILIMUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 739,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "64690C6F-80CF-4A87-932C-7D7B3D0FBF6F",
    "patient_ID": "TCGA.XV.A9W5",
    "bcr_drug_barcode": "TCGA-XV-A9W5-D68531",
    "bcr_drug_uuid": "523AB40D-5CBE-442F-8D44-24F34CDFCA13",
    "form_completion_date": "2014-11-24",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 264,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "04ADD7F0-D212-486E-AE70-D41D8112F523",
    "patient_ID": "TCGA.XV.AB01",
    "bcr_drug_barcode": "TCGA-XV-AB01-D68530",
    "bcr_drug_uuid": "41F9B152-557B-4624-9F4E-8612E3858759",
    "form_completion_date": "2014-11-24",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "19E9BA4B-8F8E-4899-B667-B49FDD7EF6F4",
    "patient_ID": "TCGA.YG.AA3O",
    "bcr_drug_barcode": "TCGA-YG-AA3O-D59917",
    "bcr_drug_uuid": "1EE9A99D-FE85-4000-8C6E-8547FA9D00FF",
    "form_completion_date": "2014-5-23",
    "pharmaceutical_therapy_drug_name": "YERVOY",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1081,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "19E9BA4B-8F8E-4899-B667-B49FDD7EF6F4",
    "patient_ID": "TCGA.YG.AA3O",
    "bcr_drug_barcode": "TCGA-YG-AA3O-D59918",
    "bcr_drug_uuid": "0C714B72-9B80-4436-B8E8-4236A49D60BB",
    "form_completion_date": "2014-5-23",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 977,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1006,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F1713C39-26B8-4667-A08B-F8CF6D2B8E13",
    "patient_ID": "TCGA.YG.AA3P",
    "bcr_drug_barcode": "TCGA-YG-AA3P-D59357",
    "bcr_drug_uuid": "0F4E8490-1A02-4315-A06B-B306590BEA2E",
    "form_completion_date": "2014-5-23",
    "pharmaceutical_therapy_drug_name": "YERVOY",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 385,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "590B5E18-D837-4C0E-BECF-80520DB57C0F",
    "patient_ID": "TCGA.Z2.A8RT",
    "bcr_drug_barcode": "TCGA-Z2-A8RT-D68276",
    "bcr_drug_uuid": "52CF8234-CF27-4C04-908B-DEE01C3C4560",
    "form_completion_date": "2014-11-14",
    "clinical_trial_drug_classification": "PHASE III",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 722,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "5B10234B-6189-449F-8886-D0D44A729CED",
    "patient_ID": "TCGA.Z2.AA3V",
    "bcr_drug_barcode": "TCGA-Z2-AA3V-D61457",
    "bcr_drug_uuid": "A60A980E-107F-4118-8145-FEEE595C11BB",
    "form_completion_date": "2014-6-30",
    "clinical_trial_drug_classification": "PHASE III",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 228,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  }
]
